<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fine-Tuning ChemBERTa for Predicting Inhibitory Activity Against TDP1 Using Deep Learning - Health AI Hub</title>
    <meta name="description" content="This paper introduces a deep learning framework leveraging fine-tuned ChemBERTa, a pre-trained chemical language model, to quantitatively predict the pIC50 valu">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Fine-Tuning ChemBERTa for Predicting Inhibitory Activity Against TDP1 Using Deep Learning</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.04252v1" target="_blank">2512.04252v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-03
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Baichuan Zeng
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.98 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.04252v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.04252v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a deep learning framework leveraging fine-tuned ChemBERTa, a pre-trained chemical language model, to quantitatively predict the pIC50 values of small molecules against Tyrosyl-DNA Phosphodiesterase 1 (TDP1) directly from their SMILES strings. Utilizing a large dataset and addressing activity imbalance, the model demonstrates superior performance over classical baselines and competitive results with Random Forest, providing an accurate and robust tool for accelerating TDP1 inhibitor discovery.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Predicting TDP1 inhibitors is crucial for developing new strategies to overcome cancer chemoresistance, a major obstacle in effective cancer treatment. This computational tool significantly speeds up the identification of potential drug candidates.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This research applies deep learning (specifically, fine-tuned chemical language models like ChemBERTa) to accelerate drug discovery in oncology. It enables the accurate prediction of inhibitory potency (pIC50 values) of potential drug candidates against a specific therapeutic target (TDP1, relevant for cancer chemoresistance) directly from their molecular SMILES strings. This AI application serves as a robust, structure-free computational tool for virtual screening and prioritizing novel compounds for experimental testing, thereby speeding up the development of new cancer drugs.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the critical challenge of predicting inhibitory potency against TDP1, a key target for overcoming cancer chemoresistance, in early drug discovery.</li>
                    
                    <li>Develops a deep learning framework for quantitative regression of pIC50 values using fine-tuned variants of ChemBERTa, a pre-trained chemical language model, inputting molecular SMILES strings.</li>
                    
                    <li>Employs a large-scale consensus dataset of 177,092 compounds, addressing severe activity imbalance (only 2.1% active) through stratified data splits and sample weighting.</li>
                    
                    <li>Systematically evaluates two pre-training strategies: Masked Language Modeling (MLM) and Masked Token Regression (MTR).</li>
                    
                    <li>Outperforms classical baselines (Random Predictor) in both regression accuracy and virtual screening utility, and achieves competitive performance compared to Random Forest.</li>
                    
                    <li>Achieves high virtual screening metrics: Enrichment Factor EF@1% of 17.4 and Precision Precision@1% of 37.4 among top-ranked predictions.</li>
                    
                    <li>The resulting model is validated through rigorous ablation and hyperparameter studies, providing a robust, ready-to-deploy, 3D-structure-free tool for prioritizing TDP1 inhibitors for experimental testing.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study utilized a deep learning framework based on fine-tuned ChemBERTa, a pre-trained chemical language model. It performed quantitative regression of pIC50 values directly from SMILES strings. A large consensus dataset of 177,092 compounds was used, with data imbalance (2.1% active) addressed via stratified data splits and sample weighting. Two pre-training strategies, Masked Language Modeling (MLM) and Masked Token Regression (MTR), were evaluated. The model underwent rigorous ablation and hyperparameter studies for validation.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The fine-tuned ChemBERTa model accurately predicts TDP1 inhibitory activity (pIC50) from SMILES strings, outperforming random baselines in regression accuracy and virtual screening utility. It showed competitive performance with Random Forest, achieving high enrichment factors (EF@1% 17.4) and precision (Precision@1% 37.4) for top-ranked predictions. This demonstrates the transformative potential of chemical transformers in target-specific drug discovery without requiring 3D structural information.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This robust and ready-to-deploy computational tool can significantly accelerate early drug discovery efforts by accurately prioritizing potential TDP1 inhibitors for experimental testing. This will aid in the development of novel therapeutic agents to combat cancer chemoresistance, ultimately improving cancer treatment outcomes.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any limitations of the methodology or findings.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly state any future research directions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Cancer Research</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">TDP1</span>
                    
                    <span class="tag tag-keyword">ChemBERTa</span>
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">pIC50</span>
                    
                    <span class="tag tag-keyword">Chemoresistance</span>
                    
                    <span class="tag tag-keyword">SMILES</span>
                    
                    <span class="tag tag-keyword">Virtual Screening</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Predicting the inhibitory potency of small molecules against Tyrosyl-DNA Phosphodiesterase 1 (TDP1)-a key target in overcoming cancer chemoresistance-remains a critical challenge in early drug discovery. We present a deep learning framework for the quantitative regression of pIC50 values from molecular Simplified Molecular Input Line Entry System (SMILES) strings using fine-tuned variants of ChemBERTa, a pre-trained chemical language model. Leveraging a large-scale consensus dataset of 177,092 compounds, we systematically evaluate two pre-training strategies-Masked Language Modeling (MLM) and Masked Token Regression (MTR)-under stratified data splits and sample weighting to address severe activity imbalance which only 2.1% are active. Our approach outperforms classical baselines Random Predictor in both regression accuracy and virtual screening utility, and has competitive performance compared to Random Forest, achieving high enrichment factor EF@1% 17.4 and precision Precision@1% 37.4 among top-ranked predictions. The resulting model, validated through rigorous ablation and hyperparameter studies, provides a robust, ready-to-deploy tool for prioritizing TDP1 inhibitors for experimental testing. By enabling accurate, 3D-structure-free pIC50 prediction directly from SMILES, this work demonstrates the transformative potential of chemical transformers in accelerating target-specific drug discovery.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>